JBM Healthcare Announces FY2023 Annual Results
Net Profit Surges 132% to HK$57.1 Million Proprietary Chinese Medicines Witness Robust Growth of 54.5% Recommends Final Dividend of HK2.5 Cents Per Share
HONG KONG, Jun 15, 2023 - (ACN Newswire) - JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the "Group"), a leading branded healthcare products marketer and distributor in Hong Kong, today announced the annual results of the Group for the year ended 31 March 2023 ("FY2023" or the "Reporting Period").
KEY HIGHLIGHTS -- Year-on-year revenue up by 28.1% totalled HK$520.3 million -- Profit attributable to equity shareholders increased by 132%, amounting to HK$57.1 million -- Proprietary Chinese medicines business witnessed robust growth of 54.5% -- The Board recommends a final dividend of HK2.5 cents per share -- Cross-border e-commerce business gained tremendous traction alongside expanded product offerings and growing customer traffic -- Rosy growth prospect of the proprietary Chinese medicine business substantiated by increasing consumer acceptance and a broadened geographic reach
Amidst the steady recovery in Hong Kong's economy fueled by the gradual easing of COVID-19 restrictions, the Group witnessed a notable rise in overall sales, propelled by improving consumer sentiment. During the Reporting Period, the Group's total revenue was HK$520.3 million, reflecting a remarkable growth of 28.1%, driven primarily by the strong performance of proprietary Chinese medicines.
The Group's gross profit amounted to HK$205.5 million, an increase of 27.2%, while the consolidated profit attributable to equity shareholders amounted to HK$57.1 million, a significant increase of 132%. Such an increase was mainly attributable to the uplifted revenue of the Group's cross-border e-commerce business, alongside the strong performance of the proprietary Chinese medicine business.
The Board recommends a final dividend of HK2.5 cents per share. Including the interim dividend of HK0.5 cent per share already paid, the total dividend for FY2023 would be HK3.0 cents per share.
Market-Driven Portfolio Bolstered Resilient Performance
Despite the market challenges posed by COVID-19, JBM Healthcare's portfolio demonstrated resilience during the Reporting Period. Carrying a range of well-known brands spanning branded medicines, proprietary Chinese medicines and health supplements, the Group delivered consistent revenue growth, driven primarily by strong performance in proprietary Chinese medicines coupled with a promising cross-border e-commerce sales trend.
On the proprietary Chinese medicines business, sales revenue surged by 54.5% to HK$359.8 million, as the stabilisation of the pandemic led to a gradual recovery in retail sentiment and increased demand for Chinese medicine services. This growth was driven by the strong momentum of the Concentrated Chinese Medicine Granules ("CCMG") business, as well as the significant increase in sales of Po Chai Pills. Cross-Border E-commerce Development Gained Traction
The Group's cross-border e-commerce business in the PRC has gained strong momentum, experiencing significant growth compared to the previous period.
The Group's two self-operated flagship stores on Tmall Global Marketplace and JD Worldwide made significant strides in expanding the market share and customer base during the Reporting Period. With the strong performance of the Group's leading brand product, Ho Chai Kung Tji Thung San, our flagship store achieved a top ranking on Tmall and secured the No.1 position in the "OTC-International" and "OTC-Pain Killer" categories during the Double 12 Event. Other popular brand products like Po Chai Pills also demonstrated promising growth in the Reporting Period.
The Group has also expanded its domestic e-platform, Go-Smart, allowing prospective customers in the PRC to gain access to making purchases on JBM Healthcare's health supplement products.
Capturing Growth Potential in Chinese Medicines
To facilitate the entry of Hong Kong traditional propriety Chinese medicines into the Greater Bay Area, the government of Guangdong Province has introduced streamlined measures to enable eligible proprietary Chinese medicines for external use to apply for registration with the Guangdong Provincial Medical Products Administration (GDMPA). Leveraging this favorable policy, the Group has successfully obtained registration approval for its medicated oil brands, Shiling Oil and Konsodona Medicated Oil, in the Greater Bay Area, anticipating the launch of the products in the market in the near term.
Acquisition to Enhance Portfolio and Platform
The Group recently completed the acquisition of a joint venture company specialising in developing and marketing health and wellness product brands. The joint venture company has established a robust distribution network for proprietary medicines and health and wellness products, including the development of supplement brands "SEASONS" and "Slimming Expert". With this acquisition, the Group aims to enhance its health and wellness portfolio and distribution platform, capitalising on the rising consumer healthcare market in the Greater Bay Area.
Mr. Patrick Wong, Chief Executive Officer of JBM Healthcare, said, "In FY2023, JBM Healthcare demonstrated resilience despite challenges from the fifth wave of the epidemic and external market pressures. Our strengths lie in our robust portfolio of well-known brands, alongside strong commercial execution and adaptability to market changes.
We are optimistic about the healthcare sector's future outlook. Our focus is on promoting operational excellence as we pursue growth strategies. These include expanding our e-commerce platforms, leveraging the potential of proprietary Chinese medicines in the Greater Bay Area, aligning our product portfolio with a strong commercial execution. By doing so, we aim to provide consumers with high-quality branded healthcare products that help them manage their health effectively, advancing our mission of Enabling Better Health Through Self-Care."
About JBM (Healthcare) Limited (Stock Code: 2161) JBM Healthcare is a Hong Kong-based company that markets and distributes branded healthcare products across Greater China, Southeast Asia and certain other countries. The Group is a unique sector player with marketing expertise and a drug heritage that prioritises product efficacy and quality to meet consumers' healthcare needs. As a renowned healthcare brand operator in Hong Kong, the Group carries a wide-ranging portfolio of branded healthcare products comprising branded medicines, proprietary Chinese medicines and health and wellness products, which include well-recognised household brands such as Po Chai Pills, Ho Chai Kung Tji Thung San, Contractubex, BITE-X, Mederma for Kids, Tong Tai Chung Woodlok Oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling Oil and Konsodona Medicated Oil. JBM Healthcare has been a constituent stock of the MSCI Hong Kong Micro Cap Index since 27 May 2021. For more details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk
For media inquiries, please contact: Strategic Financial Relations Limited Vicky Lee Tel: (852) 2864 4834 Email: vicky.lee@sprg.com.hk Rachel Ko Tel: (852) 2114 2370 Email: rachel.ko@sprg.com.hk Katrina Hui Tel: (852) 2114 4318 Email: katrina.hui@sprg.com.hk Fax: (852) 2527 1196
Source: JBM (Healthcare) Limited Sectors: Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report Nov 22, 2024 22:42 JST
| Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025 Nov 22, 2024 11:00 JST
| NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth Nov 21, 2024 22:59 JST
| Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan Nov 21, 2024 15:35 JST
| Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP Nov 21, 2024 09:00 JST
| ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study Nov 20, 2024 23:05 JST
| Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center Nov 20, 2024 15:30 JST
| Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan Nov 20, 2024 11:51 JST
| Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements Nov 20, 2024 10:24 JST
| Kingsoft Announces 2024 Third Quarter Results Nov 19, 2024 18:54 JST
| NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System Nov 19, 2024 15:30 JST
| Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings Nov 19, 2024 09:02 JST
| CleverTap Recognized as a Strong Performer in Cross-Channel Marketing Hubs, Q4 2024 Report Nov 18, 2024 23:30 JST
| World's First Successful Trial of Quantum Tokens Created Using Quantum Technology Nov 18, 2024 17:29 JST
| Fujitsu and SAP Fioneer enter partnership to accelerate digital transformation in the insurance industry and deliver services that contribute to customers' sustainable business Nov 18, 2024 12:31 JST
| Expanding Possibilities with the Liquid Hydrogen-Powered GR Corolla in the Season Final Round Nov 18, 2024 09:25 JST
| COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding Nov 16, 2024 18:00 JST
| Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki Nov 15, 2024 18:58 JST
| Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment) Nov 15, 2024 17:33 JST
| Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease Nov 15, 2024 14:31 JST
|
More Latest Release >>
|